Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma.

Dong-Yang DingXiao-Jie GanJia-Ning ZhangGuo-Jun HouQi-Fei TaoDa-Peng SunWen LiYuan YangWen-Bin DingJian YuLei Liu Fu Yang Wei-Ping Zhou Sheng-Xian Yuan

Published in: British journal of cancer (2022)

In summary, we found a key molecule-TSP1-that can predict and improve the sensitivity of ICC patients to gemcitabine chemotherapy, which is of great significance for the treatment of advanced cholangiocarcinoma.

Keyphrases

locally advanced
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
rectal cancer
squamous cell carcinoma
prognostic factors
radiation therapy
patient reported outcomes
combination therapy
patient reported
replacement therapy